Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Free Market Concept Not Applicable In Pharma Sector, Says India NPPA Chairman A.K. Banerjee: An Interview With PharmAsia News

This article was originally published in PharmAsia News

Executive Summary

While the need for price control of drugs continues to be a hot topic for debate, Dr A.K. Banerjee, the man carrying the onus of regulating drug prices in India as the chairman of the National Pharmaceuticals Pricing Authority, presents his viewpoint to PharmAsia News' India bureau on the need for price control in the country.

You may also be interested in...



Indian Parliamentary Committee Lashes Out At Pricing Watchdog NPPA

The committee is concerned about the huge gap between claims raised by the National Pharmaceuticals Pricing Authority for overcharging and the actual amounts recovered, so far less than 10 percent of the total.

Indian Parliamentary Committee Lashes Out At Pricing Watchdog NPPA

The committee is concerned about the huge gap between claims raised by the National Pharmaceuticals Pricing Authority for overcharging and the actual amounts recovered, so far less than 10 percent of the total.

Indian Parliamentary Committee Lashes Out At Pricing Watchdog NPPA

NEW DELHI - Concerned by the slugglish performance of the pricing of medicines - in recovering funds from defaulting drug makers, the Parliamentary Standing Committee on chemicals and fertilizers has asked the National Pharmaceuticals Pricing Authority to bring the process up to speed

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

SC072357

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel